Beyoglu Eye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Memorial Sisli Hospital, Istanbul, Turkey.
Clin Drug Investig. 2020 Feb;40(2):119-128. doi: 10.1007/s40261-019-00865-7.
Patients with diabetic macular edema may not have optimal outcomes even with monthly ranibizumab intravitreal injections. A corticosteroid implant might be considered in such patients. The objective of this study was to compare the outcomes of switching from ranibizumab to an intravitreal dexamethasone implant after three or six consecutive monthly injections of ranibizumab.
Patients with treatment-naïve diabetic macular edema who showed a poor anatomical response to three or six consecutive intravitreal ranibizumab injections and received an intravitreal dexamethasone implant were enrolled in this retrospective study. Patients were divided into two groups as early- and late-switch groups. The early-switch group consisted of the patients who initially received three consecutive monthly ranibizumab injections and the late-switch group consisted of the patients who initially received six consecutive monthly ranibizumab injections and switched to a dexamethasone implant because of a poor anatomical response. Best corrected visual acuity and central retinal thickness at the baseline and 3, 6, 9, and 12 months in the study population were recorded.
Sixty-eight eyes of 68 patients were included. The early-switch group consisted of 34 eyes and the late-switch group consisted of 34 eyes. The mean change in best corrected visual acuity was similar between the two groups at 3, 9, and 12 months; however, it was significantly better in the early-switch group than the late-switch group at 6 months. The change in central retinal thickness was similar between the two groups at 3, 9, and 12 months; however, it was significantly better in the early-switch group than the late-switch group at 6 months.
Although both early switching and late switching are similar in terms of providing functional and morphological improvement, early switching appeared better for ensuring patient well-being in the early period and improving patient adherence.
即使每月接受雷珠单抗玻璃体内注射,糖尿病黄斑水肿患者的治疗效果也可能并不理想。对于此类患者,可能需要考虑使用皮质类固醇药物。本研究的目的是比较连续接受 3 或 6 个月雷珠单抗玻璃体注射治疗后转换为玻璃体内地塞米松植入物的疗效。
本回顾性研究纳入了对连续 3 或 6 个月雷珠单抗玻璃体内注射治疗反应不佳且接受玻璃体内地塞米松植入物治疗的初治糖尿病黄斑水肿患者。患者分为早期转换组和晚期转换组。早期转换组包括最初接受连续 3 个月雷珠单抗治疗的患者,晚期转换组包括最初接受连续 6 个月雷珠单抗治疗且由于解剖学反应不佳而转换为地塞米松植入物的患者。记录研究人群的最佳矫正视力和中央视网膜厚度在基线和 3、6、9 和 12 个月时的变化。
纳入 68 例 68 只眼。早期转换组包括 34 只眼,晚期转换组包括 34 只眼。两组患者在 3、9 和 12 个月时的最佳矫正视力变化相似,但在 6 个月时早期转换组明显优于晚期转换组。两组患者在 3、9 和 12 个月时中央视网膜厚度的变化相似,但在 6 个月时早期转换组明显优于晚期转换组。
虽然早期转换和晚期转换在提供功能和形态改善方面相似,但早期转换在早期改善患者舒适度和提高患者依从性方面似乎更好。